Investors in Cytokinetics May Have Lead Role in Securities‑Fraud Lawsuit

A national shareholder‑rights law firm, The Schall Law Firm, has issued a notice to investors that a class action lawsuit has been filed on behalf of shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b‑5. The period in question spans from December 27, 2023 to May 6, 2025, and investors who purchased the company’s securities during that time are encouraged to contact the firm by November 17, 2025 to discuss taking a leadership role in the proceeding. According to the complaint, Cytokinetics reportedly misled the market by maintaining that it expected FDA approval of its NDA for aficamten in the second half of 2025, while failing to disclose that it had not yet submitted a required Risk Evaluation and Mitigation Strategy (REMS) which could delay FDA review. The company revealed on May 6 that it had multiple pre‑NDA meetings with the FDA regarding safety and risk mitigation but still filed without submitting the REMS, triggering alleged investor losses once the truth emerged. #CytokineticsLawsuit #InvestorRights #SecuritiesFraud #ShareholderAction #SlimScan #GrowthStocks #CANSLIM